Filter Results:
(611)
Show Results For
- All HBS Web
(1,026)
- People (4)
- News (257)
- Research (611)
- Events (9)
- Multimedia (24)
- Faculty Publications (398)
Show Results For
- All HBS Web
(1,026)
- People (4)
- News (257)
- Research (611)
- Events (9)
- Multimedia (24)
- Faculty Publications (398)
Sort by
- 25 Oct 2016
- First Look
October 25, 2016
insulate consumers from cost sharing, thereby undermining insurers’ ability to influence drug utilization. We study the impact of copay coupons on branded drugs first facing generic entry between 2007 and... View Details
Keywords: Sean Silverthorne
- 07 Aug 2007
- First Look
First Look: August 7, 2007
and issues around current practices. Purchase this note: http://www.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=807124 U.S. Food and Drug Administration Harvard Business School Note 807-050 Describes the U.S. FDA with particular... View Details
Keywords: Martha Lagace
- 15 Dec 2014
- Research & Ideas
Deconstructing the Price Tag
expenses incurred. For example, R&D expenditures in the pharmaceutical industry involve more than just the cost of producing one particular drug. Many drugs may have to fail before one succeeds, and that one hit View Details
- 23 Aug 2016
- First Look
August 23, 2016
particular, we examine how individuals’ prior experiences and the experiences of those around them alter their belief perseverance in operational decisions after the revelation of negative news. We draw on an exogenous announcement of negative news by the Food and... View Details
Keywords: Sean Silverthorne
- 01 Jul 2008
- First Look
First Look: July 1, 2008
establish a proposed alliance with a pharmaceutical firm? Should it create a nutraceuticals business in parallel to its effort to develop anti-aging therapeutics? And, should it in-license a second drug development candidate? Purchase... View Details
Keywords: Martha Lagace
- 14 Dec 2011
- Research & Ideas
The New Measures for Improving Nonprofit Performance
using systems thinking and complexity theory to help us understand the challenges at the ecosystem level. There's also growing attention to using randomized control trials in the social sector, which we tend to associate with drug trials.... View Details
Keywords: by Julia Hanna
- 20 May 2016
- Op-Ed
World Health Organization Lacks Leadership to Combat Pandemics
greater role in WHO governance and if there are guarantees of purchase contracts for new drugs and vaccines at sensible prices. Both seem unlikely, as the WHO's culture has always winced at cooperation with the private sector. WHO's track... View Details
- 14 Jul 2006
- Op-Ed
The Case for Consumer-Driven Medicaid
diabetic and asthmatic enrollees due to increased testing and drug utilization, while management consulting firm McKinsey found that consumer-driven enrollees were more likely to "very carefully follow treatment regimens for chronic... View Details
Keywords: by Regina E. Herzlinger
- 18 Apr 2017
- First Look
First Look at New Ideas, April 18
M&A) and Werner Baumann (CFO) have to decide whether to increase the cash portion of their $14.2 billion offer and/or amend the terms of a proposed joint venture (JV) with Merck involving cardiovascular drugs that had been included in... View Details
Keywords: by Sean Silverthorne
- 27 Jan 2003
- Research & Ideas
New Cluster Mapping Project Helps Companies Locate Facilities
A: There is some heartening progress. The word is out among retailers about the under-served market in inner cities. Drug chains, such as Walgreen's, and many other retailers, such as Home Depot, are pursuing this opportunity to good... View Details
Keywords: by Sean Silverthorne
- 12 May 2009
- First Look
First Look: May 12, 2009
their practices. Sermo earns revenue by charging clients who would value early information regarding the effectiveness of new drugs and medical devices-investment managers, pharmaceutical companies, and regulatory authorities. Clients... View Details
Keywords: Martha Lagace
- 13 Sep 2011
- First Look
First Look: September 13
come primarily from the non-drug treatment (87.4% and 70.2% respectively), whereas gains from detailing come at the expense of competing drugs (84%). By contrast, the random coefficient logit model predicts that gains from DTCA, M&E,... View Details
Keywords: Sean Silverthorne
- 18 Sep 2007
- First Look
First Look: September 18, 2007
http://www.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=907025 NatuRi Corporation Harvard Business School Case 807-027 NatuRi Corporation was a start up, founded in 2005, aiming to manufacture a cholesterol-lowering drug made from... View Details
Keywords: Martha Lagace
- 04 Aug 2009
- First Look
First Look: August 4
to second-line drug regimens, 3.8% had died, and only one patient had been lost to follow up. A costing analysis done by the Clinton HIV/AIDS Initiative suggested that the model could feasibly be spread to other districts. Dr. Agnes... View Details
Keywords: Martha Lagace
- 02 Aug 2004
- Research & Ideas
Health Care Research and Prospects
series on AIDS in Africa and how pharmaceutical companies should think about the issues and how they might respond. Sandra Sucher has done a really wonderful case on Gleevec, which is a drug for treating chronic myeloid leukemia. She is... View Details
- 04 Jun 2007
- Research & Ideas
Is Health Care Making You Better—or Dead?
mother gave me a copy of The Jungle by Upton Sinclair. I was very struck by that book. I find the writing, in retrospect, really wretched, but the kind of passion that said, "Here is an awful system," was pivotal in getting food and View Details
- 15 Feb 2012
- Op-Ed
Occupy Wall Street Protestors Have a Point
unaffordable (which the pharmaceutical company Cipla did with HIV/AIDS drugs in Africa), and that brought housing to urban poor (one of building materials maker CEMEX's accomplishments in Mexico). Based on our research, we believe the... View Details
- 12 Feb 2008
- First Look
First Look: February 12, 2007
stake of 9.5% in Ligand Pharmaceuticals, Inc., a specialty pharmaceutical company. Third Point believed that Ligand had a strong drug portfolio and pipeline but that it was highly undervalued due to poor management. After gaining board... View Details
Keywords: Martha Lagace
- 24 Jul 2007
- First Look
First Look: July 24, 2007
the formation and rapid growth of a drug-testing company. The company needs to decide whether to enter the painkiller testing market, in addition to growing its drug treatment center business. Purchase this case:... View Details
Keywords: Martha Lagace
- 21 Apr 2009
- First Look
First Look: April 21, 2009
Industry Location Author:Arthur A. Daemmrich Abstract A consumer-oriented model for drug development and use has attracted attention in recent years as an alternative to the much-maligned approach of mass-marketing blockbuster drugs. In a... View Details
Keywords: Martha Lagace